Abstract

Case Series

Adalimumab in the Treatment of Complex Sarcoidosis-related Inflammatory Eye Disease: A Case Series

Mina Al-Awqati, Supritha Prasad*, Valeria Esparza, Jacqueline Jansz, Wuily Carpio, Christian Ascoli, Huan Chang, Pooja Bhat, Ann-Marie Lobo-Chan and Nadera Sweiss

Published: 21 May, 2024 | Volume 8 - Issue 1 | Pages: 001-003

Background: Sarcoidosis is a systemic granulomatous inflammatory disease that is associated with inflammatory eye manifestations such as uveitis, cystoid macular edema, and retinal vasculitis. Although Corticosteroids (CS) have traditionally been the mainstay of treatment, there is a clinical need and growing interest in exploring alternative therapeutic options for patients who are refractory to or intolerant of CS or require long-term steroid-sparing agents. 
Purpose: This case series aims to describe the effectiveness of adalimumab, an anti-tumor necrosis factor (TNF)-α monoclonal antibody, in the management of complex sarcoidosis-related inflammatory eye disease via reduction in CS dosage and ocular exam findings before and after initiation of adalimumab therapy.
Method: A retrospective chart review of patients between 2010 and 2023 seen at our academic center’s rheumatology and eye clinics was conducted, with 5 patients meeting the inclusion criteria. 
Results: Most patients were able to lower, discontinue, or remain off oral CS, while all 5 patients demonstrated a reduction in uveitis activity, Cystoid Macular Edema (CME), and/or retinal vasculitis. 
Conclusion: These findings suggest a potential role for adalimumab as an effective and safe therapeutic option in the management of complex sarcoidosis-related inflammatory eye disease.

Read Full Article HTML DOI: 10.29328/journal.avm.1001018 Cite this Article Read Full Article PDF

References

  1. Pasadhika S, Rosenbaum JT. Ocular Sarcoidosis. Clin Chest Med. 2015 Dec;36(4):669-83. doi: 10.1016/j.ccm.2015.08.009. PMID: 26593141; PMCID: PMC4662043.
  2. Giorgiutti S, Jacquot R, El Jammal T, Bert A, Jamilloux Y, Kodjikian L, Sève P. Sarcoidosis-Related Uveitis: A Review. J Clin Med. 2023 Apr 29;12(9):3194. doi: 10.3390/jcm12093194. PMID: 37176633; PMCID: PMC10178951.
  3. Rosenbaum JT, Sibley CH, Lin P. Retinal vasculitis. Curr Opin Rheumatol. 2016 May;28(3):228-35. doi: 10.1097/BOR.0000000000000271. PMID: 26945335; PMCID: PMC4893321.
  4. Riancho-Zarrabeitia L, Calvo-Río V, Blanco R, Mesquida M, Adan AM, Herreras JM, Aparicio Á, Peiteado-Lopez D, Cordero-Coma M, García Serrano JL, Ortego-Centeno N, Maíz O, Blanco A, Sánchez-Bursón J, González-Suárez S, Fonollosa A, Santos-Gómez M, González-Vela C, Loricera J, Pina T, González-Gay MA. Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients. Semin Arthritis Rheum. 2015 Dec;45(3):361-8. doi: 10.1016/j.semarthrit.2015.05.010. Epub 2015 May 21. PMID: 26092330.
  5. Baughman RP, Lower EE, Ingledue R, Kaufman AH. Management of ocular sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2012 Mar;29(1):26-33. PMID: 23311120.
  6. Leclercq M, Andrillon A, Maalouf G, Sève P, Bielefeld P, Gueudry J, Sené T, Moulinet T, Rouvière B, Sène D, Desbois AC, Domont F, Touhami S, El Chamieh C, Cacoub P, Bodaghi B, Biard L, Saadoun D. Anti-Tumor Necrosis Factor α versus Tocilizumab in the Treatment of Refractory Uveitic Macular Edema: A Multicenter Study from the French Uveitis Network. Ophthalmology. 2022 May;129(5):520-529. doi: 10.1016/j.ophtha.2021.11.013. Epub 2021 Nov 16. PMID: 34793830.
  7. Li J, Zhang Z, Wu X, Zhou J, Meng D, Zhu P. Risk of Adverse Events After Anti-TNF Treatment for Inflammatory Rheumatological Disease. A Meta-Analysis. Front Pharmacol. 2021 Nov 1;12:746396. doi: 10.3389/fphar.2021.746396. PMID: 34790122; PMCID: PMC8591221.
  8. Bonovas S, Minozzi S, Lytras T, González-Lorenzo M, Pecoraro V, Colombo S, Polloni I, Moja L, Cinquini M, Marino V, Goletti D, Matucci A, Tocci G, Milano GM, Scarpa R, Cantini F. Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf. 2016 Dec;15(sup1):35-54. doi: 10.1080/14740338.2016.1238458. PMID: 27924644.
  9. Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis. 2009 Jul;68(7):1136-45. doi: 10.1136/ard.2008.091025. Epub 2008 Aug 27. PMID: 18753157.

Figures:

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?